Found: 96
Select item for more details and to access through your institution.
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 11, p. 3707, doi. 10.1007/s00262-023-03522-3
- By:
- Publication type:
- Article
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 7, p. 2127, doi. 10.1007/s00262-023-03398-3
- By:
- Publication type:
- Article
BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.
- Published in:
- Journal of Personalized Medicine, 2024, v. 14, n. 4, p. 394, doi. 10.3390/jpm14040394
- By:
- Publication type:
- Article
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges.
- Published in:
- Cancers, 2024, v. 16, n. 14, p. 2610, doi. 10.3390/cancers16142610
- By:
- Publication type:
- Article
Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6074, doi. 10.3390/cancers14246074
- By:
- Publication type:
- Article
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5925, doi. 10.3390/cancers14235925
- By:
- Publication type:
- Article
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma.
- Published in:
- Cancers, 2022, v. 14, n. 13, p. N.PAG, doi. 10.3390/cancers14133249
- By:
- Publication type:
- Article
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
- Published in:
- Cancers, 2021, v. 13, n. 21, p. 5403, doi. 10.3390/cancers13215403
- By:
- Publication type:
- Article
FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy.
- Published in:
- Cancers, 2021, v. 13, n. 4, p. 814, doi. 10.3390/cancers13040814
- By:
- Publication type:
- Article
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.
- Published in:
- Cancers, 2021, v. 13, n. 1, p. 6, doi. 10.3390/cancers13010006
- By:
- Publication type:
- Article
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2948, doi. 10.3390/cancers12102948
- By:
- Publication type:
- Article
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2645, doi. 10.3390/cancers12092645
- By:
- Publication type:
- Article
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1425, doi. 10.3390/cancers12061425
- By:
- Publication type:
- Article
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 3, p. 666, doi. 10.3390/cancers12030666
- By:
- Publication type:
- Article
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1431, doi. 10.3390/cancers11101431
- By:
- Publication type:
- Article
MET and Small-Cell Lung Cancer.
- Published in:
- Cancers, 2014, v. 6, n. 4, p. 2100, doi. 10.3390/cancers6042100
- By:
- Publication type:
- Article
Overexpression of microRNA-486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1.
- Published in:
- International Journal of Molecular Medicine, 2021, v. 47, n. 6, p. N.PAG, doi. 10.3892/ijmm.2021.4950
- By:
- Publication type:
- Article
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios.
- Published in:
- Molecular Biology Reports, 2021, v. 48, n. 4, p. 3485, doi. 10.1007/s11033-021-06322-z
- By:
- Publication type:
- Article
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population.
- Published in:
- Oncologist, 2019, v. 24, n. 11, p. e1165, doi. 10.1634/theoncologist.2018-0737
- By:
- Publication type:
- Article
Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study.
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. e327, doi. 10.1634/theoncologist.2018-0618
- By:
- Publication type:
- Article
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study.
- Published in:
- Clinical Medicine Insights: Oncology, 2021, p. 1, doi. 10.1177/11795549211043427
- By:
- Publication type:
- Article
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study.
- Published in:
- Clinical Medicine Insights: Oncology, 2021, v. 15, p. 1, doi. 10.1177/11795549211043427
- By:
- Publication type:
- Article
Maintenance therapy in NSCLC: why? To whom? Which agent?
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2011, v. 30, n. 1, p. 50, doi. 10.1186/1756-9966-30-50
- By:
- Publication type:
- Article
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.
- Published in:
- Molecules, 2019, v. 24, n. 24, p. 4443, doi. 10.3390/molecules24244443
- By:
- Publication type:
- Article
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 5, p. 473, doi. 10.1016/j.cllc.2021.02.014
- By:
- Publication type:
- Article
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 4, p. 361, doi. 10.1016/j.cllc.2020.06.028
- By:
- Publication type:
- Article
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
- Published in:
- 2020
- By:
- Publication type:
- case study
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Italian Multicenter Phase III Randomized Study of Cisplatin--Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial.
- Published in:
- Clinical Lung Cancer, 2015, v. 16, n. 1, p. 67, doi. 10.1016/j.cllc.2014.09.001
- By:
- Publication type:
- Article
Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 6, p. 470, doi. 10.1016/j.cllc.2014.06.004
- By:
- Publication type:
- Article
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 6, p. 411, doi. 10.1016/j.cllc.2014.07.002
- By:
- Publication type:
- Article
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.
- Published in:
- Disease Markers, 2017, p. 1, doi. 10.1155/2017/9645940
- By:
- Publication type:
- Article
Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 17, p. 2671, doi. 10.3390/cells11172671
- By:
- Publication type:
- Article
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 3, p. 413, doi. 10.3390/cells11030413
- By:
- Publication type:
- Article
Dynamic Evaluation of Circulating miRNA Profile in EGFR -Mutated NSCLC Patients Treated with EGFR-TKIs.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 6, p. 1520, doi. 10.3390/cells10061520
- By:
- Publication type:
- Article
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920968463
- By:
- Publication type:
- Article
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920952994
- By:
- Publication type:
- Article
Atezolizumab in a C o H ort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyp E s (CHANCE trial).
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920915983
- By:
- Publication type:
- Article
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919885540
- By:
- Publication type:
- Article